- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07663799
Wearable Assessment of Thoracic, Cardiac Health and Exercise Performance Trial Prospective (WATCH-XP)
Wearable Assessment of Thoracic, Cardiac Health and Exercise Performance Trial Prospective (WATCH-XP)
Wearable health technology, particularly smartwatches, has revolutionized personal health monitoring by enabling continuous, non-invasive tracking of various physiological parameters. The potential applications of these devices in cardiology are extensive, but it is crucial to validate their accuracy against established medical-grade devices.
The Apple Watch Series 9 (Apple, USA) exemplifies the capabilities of modern smartwatches, offering a wide range of health tracking features. These include heart rate monitoring, detection of irregular heart rhythms suggestive of atrial fibrillation, electrocardiogram recording, blood oxygen level measurement, and comprehensive mobility metrics (including VO2 max, six-minute walk distance, walking speed, step length, double support time, and walking asymmetry). Many of these parameters are highly relevant for cardiovascular patients, potentially aiding in disease progression monitoring and adverse event prediction. However, there is a lack of comprehensive validation studies for these devices in specific cardiovascular disease populations.
This investigator-initiated, prospective observational study will consist of two phases: a training phase which involves 50 participants and a prospective validation phase which involves 20 participants. The study aims to validate smartwatch-based assessments using medical-grade devices and techniques. The study will focus on adult patients with congenital heart disease, pulmonary hypertension, heart failure, and coronary artery disease, as well as athletes undergoing cardiovascular assessment. By comparing smartwatch data with established clinical measurements, we seek to determine the reliability and potential clinical utility of these wearable devices in diverse cardiovascular contexts. Anonymized smartwatch data collected during the two phases will be published to a publicly registry to facilitate further research. This research will help bridge the gap between consumer-grade wearable technology and clinical practice in cardiology.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
This study is investigator-initiated, prospective observational study and will consist of two phases: a training phase and a prospective validation phase.
Training Phase (First Phase) 50 participants will undergo comprehensive baseline assessments and continuous physiological monitoring with the smartwatch. Data collected during this phase will be anonymized and exported to a public open-source training model.
At Visit 1 of the first phase, Comprehensive demographic and clinical data will be collected from each participant, Clinical Management System (CMS), Electronic Patient Record (ePR), and Clinical Data Analysis and Reporting System (CDARS) of the Hospital Authority in Hong Kong. This will include age, sex, height, weight, body mass index, and detailed medical history focusing on cardiovascular conditions. Information about current medications and smoking status will also be recorded. Additionally, participants will undergo a baseline clinical examination, including blood pressure measurement, heart rate, and a 12-lead electrocardiogram.
VO2max Participants will undergo a conventional cardiopulmonary exercise test (CPX) to determine their maximal oxygen uptake (VO2max) at Visit 1. This test will be conducted in a controlled clinical setting under the supervision of cardiologists. Participants will exercise on a treadmill while their respiratory gas exchange is measured using a metabolic cart. The exercise intensity will be gradually increased until the participant reaches volitional exhaustion or predetermined safety criteria are met. The highest oxygen uptake value achieved during the test will be recorded as the VO2max. Participant will concurrently be wearing the investigational smartwatch for pre- and post-SaO2 and VO2max assessment. This gold-standard measurement will serve as the reference for validating the smartwatch's continuous VO2max estimation.
6-Minute walk distance The 6-minute walk distance will be assessed in a hospital setting at Visit 2 of the first phase under the supervision of a research staff. Participants will be instructed to walk as far as possible in six minutes along a predetermined course, typically a straight hallway. The total distance walked will be measured and recorded. During the test, the research nurse will monitor the participant's heart rate, blood oxygen saturation, and perceived exertion at regular intervals. Participant will concurrently be wearing the investigational smartwatch for pre- and post-SaO2 and VO2max assessment.
Oxygen saturation During the follow-up period of the first phase, participants will be provided with a medical-grade pulse oximeter for home use. They will be instructed to measure their oxygen saturation once daily throughout the one-week study period. Measurements should be taken at approximately the same time each day, preferably in the morning after waking and before any strenuous activity. Participants will record their oxygen saturation readings in a provided log. These daily measurements will serve as reference points for validating the continuous oxygen saturation data collected by the smartwatch.
Prospective Validation Phase (Second Phase) 20 participants will undergo similar assessments, with the primary aim of validating the smartwatch's measurements against medical-grade devices. Data collected during this phase also will be anonymized and exported to a public open-source training model.
At the Visit of the second phase, Comprehensive demographic and clinical data will be collected from each participant, Clinical Management System (CMS), Electronic Patient Record (ePR), and Clinical Data Analysis and Reporting System (CDARS) of the Hospital Authority in Hong Kong. This will include age, sex, height, weight, body mass index, and detailed medical history focusing on cardiovascular conditions. Information about current medications and smoking status will also be recorded. Additionally, participants will undergo a baseline clinical examination, including blood pressure measurement, heart rate, and a 12-lead electrocardiogram.
VO2max Participants will undergo a conventional cardiopulmonary exercise test (CPX) to determine their maximal oxygen uptake (VO2max) at Visit 1. This test will be conducted in a controlled clinical setting under the supervision of cardiologists. Participants will exercise on a treadmill while their respiratory gas exchange is measured using a metabolic cart. The exercise intensity will be gradually increased until the participant reaches volitional exhaustion or predetermined safety criteria are met. The highest oxygen uptake value achieved during the test will be recorded as the VO2max. Participant will concurrently be wearing the investigational smartwatch for pre- and post-SaO2 and VO2max assessment. This gold-standard measurement will serve as the reference for validating the smartwatch's continuous VO2max estimation.
Tipo di studio
Iscrizione (Stimato)
Contatti e Sedi
Contatto studio
- Nome: Chun Ka Wong
- Numero di telefono: +852 2255 3111
- Email: wongeck@hku.hk
Luoghi di studio
-
-
-
Hong Kong, Hong Kong
- Department of Medicine, Queen Mary Hospital
-
Contatto:
- Chun Ka Wong
- Numero di telefono: +852 2255 3111
- Email: wongeck@hku.hk
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- Age 20 to 70 years old
- Ability to provide informed consent
- History of the following cardiovascular conditions:
- Adult congenital heart disease
- Pulmonary hypertension
- Heart failure
- Coronary artery disease
- Athletes undergoing cardiovascular assessment
Exclusion Criteria:
- Contraindication for undergoing physical exertion including cardio-pulmonary exercise testing (CPX) and 6-minute walk test (6MWT)
- Pregnancy
- Known allergy to components of the investigational product
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
|---|---|
|
WatchXP
Participants will wear the investigational smartwatch (Apple Watch Series 9) concurrently for pre- and post-SaO2 and VO2max assessment during cardiopulmonary exercise test at the visit.
|
Participant will concurrently be wearing the investigational smartwatch for pre- and post-SaO2 and VO2max assessment.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Correlation between CPX VO2max and smartwatch parameters (virtual VO2 max, physical activity parameters)
Lasso di tempo: During treadmill exercise in the day of recruitment and concurrently baseline assessment
|
VO2 max (ml/min/kg) concurrently measured with a medical-grade device and a smartwatch which has virutal VO2 max and physical activity parameters as assessed during treadmill exercise
|
During treadmill exercise in the day of recruitment and concurrently baseline assessment
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Correlation between VO2 max (ml/min/kg) obtained using medical-grade device and smartwatch
Lasso di tempo: During treadmill exercise in the day of recruitment and concurrently baseline assessment
|
VO2 max (ml/min/kg) obtained using medical-grade device and smartwatch during supervised treadmill exercise
|
During treadmill exercise in the day of recruitment and concurrently baseline assessment
|
|
Correlation between SaO2 (%) obtained using medical-grade device and smartwatch
Lasso di tempo: During treadmill exercise in the day of recruitment and concurrently baseline assessment
|
SaO2 (%) obtained using medical-grade device and smartwatch during supervised treadmill exercise
|
During treadmill exercise in the day of recruitment and concurrently baseline assessment
|
|
SaO2 (%) measured by the smartwatch
Lasso di tempo: During treadmill exercise in the day of recruitment and concurrently baseline assessment
|
SaO2 (%) measured by the smartwatch during supervised treadmill exercise
|
During treadmill exercise in the day of recruitment and concurrently baseline assessment
|
|
SaO2 (%) in participants with severe disease and participants with mild disease
Lasso di tempo: During treadmill exercise in the day of recruitment and concurrently baseline assessment
|
SaO2 (%) in participants with severe versus mild disease during supervised treadmill exercise
|
During treadmill exercise in the day of recruitment and concurrently baseline assessment
|
|
Novel markers or patterns
Lasso di tempo: During treadmill exercise in the day of recruitment and concurrently baseline assessment
|
Novel markers or patterns indicative of disease severity or predictive of adverse events as assessed during supervised treadmill exercise
|
During treadmill exercise in the day of recruitment and concurrently baseline assessment
|
Collaboratori e investigatori
Sponsor
Pubblicazioni e link utili
Pubblicazioni generali
- Wong CK, Lau YM, Lui HW, Chan WF, San WC, Zhou M, Cheng Y, Huang D, Lai WH, Lau YM, Siu CW. Automatic detection of cardiac conditions from photos of electrocardiogram captured by smartphones. Heart. 2024 Aug 14;110(17):1074-1082. doi: 10.1136/heartjnl-2023-323822.
- Guo Y, Wang H, Zhang H, Liu T, Liang Z, Xia Y, Yan L, Xing Y, Shi H, Li S, Liu Y, Liu F, Feng M, Chen Y, Lip GYH; MAFA II Investigators. Mobile Photoplethysmographic Technology to Detect Atrial Fibrillation. J Am Coll Cardiol. 2019 Nov 12;74(19):2365-2375. doi: 10.1016/j.jacc.2019.08.019. Epub 2019 Sep 2.
- Chan PH, Wong CK, Poh YC, Pun L, Leung WW, Wong YF, Wong MM, Poh MZ, Chu DW, Siu CW. Diagnostic Performance of a Smartphone-Based Photoplethysmographic Application for Atrial Fibrillation Screening in a Primary Care Setting. J Am Heart Assoc. 2016 Jul 21;5(7):e003428. doi: 10.1161/JAHA.116.003428.
- Mannhart D, Lischer M, Knecht S, du Fay de Lavallaz J, Strebel I, Serban T, Vogeli D, Schaer B, Osswald S, Mueller C, Kuhne M, Sticherling C, Badertscher P. Clinical Validation of 5 Direct-to-Consumer Wearable Smart Devices to Detect Atrial Fibrillation: BASEL Wearable Study. JACC Clin Electrophysiol. 2023 Feb;9(2):232-242. doi: 10.1016/j.jacep.2022.09.011. Epub 2023 Jan 18.
- Perez MV, Mahaffey KW, Hedlin H, Rumsfeld JS, Garcia A, Ferris T, Balasubramanian V, Russo AM, Rajmane A, Cheung L, Hung G, Lee J, Kowey P, Talati N, Nag D, Gummidipundi SE, Beatty A, Hills MT, Desai S, Granger CB, Desai M, Turakhia MP; Apple Heart Study Investigators. Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation. N Engl J Med. 2019 Nov 14;381(20):1909-1917. doi: 10.1056/NEJMoa1901183.
- Wong CK, Un KC, Zhou M, Cheng Y, Lau YM, Shea PC, Lui HW, Zuo ML, Yin LX, Chan EW, Wong ICK, Sin SWC, Yeung PPN, Chen H, Wibowo S, Wei TLN, Lee SM, Chow A, Tong RCF, Hai J, Tam FCC, Siu CW. Daily ambulatory remote monitoring system for drug escalation in chronic heart failure with reduced ejection fraction: pilot phase of DAVID-HF study. Eur Heart J Digit Health. 2022 May 7;3(2):284-295. doi: 10.1093/ehjdh/ztac024. eCollection 2022 Jun.
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie vascolari
- Malattia cardiovascolare
- Malattie cardiache
- Malattie delle vie respiratorie
- Malattie polmonari
- Anomalie congenite
- Anomalie cardiovascolari
- Ischemia miocardica
- Ipertensione
- Malattie e anomalie congenite, ereditarie e neonatali
- Arresto cardiaco
- Difetti cardiaci, congeniti
- Ipertensione, polmonare
- Malattia coronarica
Altri numeri di identificazione dello studio
- WATCH-XP
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Arresto cardiaco
-
Region SkaneIscrizione su invitoInsufficienza cardiaca Classe II della New York Heart Association (NYHA). | Insufficienza cardiaca Classe III della New York Heart Association (NYHA).Svezia
-
Yonsei UniversityReclutamentoIschemic Heart Disease | Cardiopatia Non IschemicaCorea del Sud
-
Medical University of BialystokMedical University of Lodz; Poznan University of Medical Sciences; Nicolaus Copernicus... e altri collaboratoriTerminatoInsufficienza cardiaca, sistolica | Insufficienza cardiaca con frazione di eiezione ridotta | Scompenso cardiaco Classe IV della New York Heart Association | Scompenso cardiaco Classe III della New York Heart AssociationPolonia
-
V-Wave LtdJohnson & JohnsonNon ancora reclutamentoInsufficienza cardiaca congestizia | Insufficienza cardiaca e frazione di eiezione ridotta | Scompenso cardiaco Classe III della New York Heart Association | Heart Failure Chronic
-
University of WashingtonAmerican Heart AssociationCompletatoInsufficienza cardiaca, congestizia | Alterazione mitocondriale | Scompenso cardiaco Classe IV della New York Heart AssociationStati Uniti
-
Portuguese Association of Interventional CardiologyMedtronicReclutamentoStenosi Aortica Sintomatica Grave (Definita come Classe New York Heart Association (NYHA) ≥ II)Portogallo
Prove cliniche su Apple Watch Series 9
-
Masimo CorporationCompletatoVolontari saniStati Uniti
-
The University of Hong KongCompletatoDisfunsione dell'arteria coronaria | Arresto cardiaco | Ipertensione polmonare | Cardiopatia congenitaHong Kong
-
University of ChicagoReclutamento
-
Janssen Scientific Affairs, LLCApple Inc.CompletatoFibrillazione atrialeStati Uniti
-
University Medical Center GoettingenReclutamentoArresto cardiaco | Insufficienza cardiaca, congestizia | Insufficienza cardiaca acuta | Insufficienza cardiaca con frazione di eiezione ridotta | Insufficienza cardiaca; con scompensoGermania
-
University Hospital HeidelbergThe German Heart Foundation; Klaus Tschira Stiftung, Germany; Freunde und Förderer...Completato
-
Cedars-Sinai Medical CenterNon ancora reclutamento
-
Zimmer BiometCompletatoArtrosi, ginocchio | Osteoartrite, ancaStati Uniti, Australia, Italia, Olanda
-
Stanford UniversityStryker NordicCompletatoChirurgia | Stenosi spinale | Degenerazione della colonna vertebrale | Fusione della colonna vertebrale | Malattia della colonna vertebraleStati Uniti
-
Stanford UniversityApple Inc.Terminato